All News

Insulin manufacturers are expanding insulin affordability options for patients with diabetes during the coronavirus pandemic. 

In 2 prior clinical studies, gimsilumab demonstrated favorable results in treating the novel coronavirus.

A recent meta-analysis showed an association between regular aspirin use and reduced risk of developing several cancers of the digestive tract.

The American Heart Association’s scientific statement outlines medications, procedures, and lifestyle change recommendations for individuals with both type2 diabetes and coronary artery disease.

Merck has announced the US launch of trastuzumab-dttb (Ontruzant), a biosimilar to trastuzumab (Herceptin), in both 150-mg single-dose vials and 420-mg multiple-dose vials.

As the global COVID-19 pandemic and consequent public health crisis continues on, health care providers on the frontlines of this crisis deserve all of the support needed to continue serving their patients.

GlaxoSmithKline and Sanofi have prioritized public health over competition in their agreement, announced today.

In part 2 of our video interview, Robert Brunault, PharmD, a clinical pharmacy specialist in hematology and oncology at Rhode Island Hospital and the Lifespan Cancer Institute, discussed drug shortages, FDA emergency use authorizations, and the biggest concerns for pharmacists.

Gilead shares compassionate use data for remdesivir in patients with COVID-19 and a new research paper suggests remdesivir's mechanism of action could make it effective in combatting the virus. 

“You’re basically on call 24/7, 365 days a year. That’s the biggest word of caution I would offer to someone considering this. But at the same time, the biggest reward I get is seeing sick people get better."

In collaboration with Spectrum Solutions and Accurate Diagnostic Labs, RUCDR Infinite Biologics developed the new collection approach, which utilizes saliva as the primary test biomaterial for COVID-19. 

This year may mark a dramatic difference in the development and approval of complex generic drug products.

New research has identified an association between sensory loss and novel coronavirus 2019 (COVID-19) infection.

Neurofibromatosis type 1 (NF1) is a debilitating, progressive and often disfiguring disease that usually starts early in life.

V-Go® may provide a more affordable option for insulin therapy.

OmniSYS is providing all pharmacies free access to the OmniSYS Training Center™, which guides pharmacists through all aspects of the process to operationalize COVID-19 testing

“I had been practicing for 4 years at that time and longed for the day that pharmacists would have input in patient’s pharmacotherapy. That day is here!”

In 2010, nearly 43 million of adults living in the United States, or approximately 20%, took aspirin a minimum of 3 times per week for 3 months or more.

In a video interview with Drug Topics®, Robert Brunault, PharmD, a clinical pharmacy specialist of hematology and oncology at Rhode Island Hospital and Lifespan Cancer Institute, answers questions about how the COVID-19 pandemic affects patients undergoing treatment for cancer.

Here's a roundup of the latest coronavirus-related news.

The letter asks the vice president to increase manufacturing of these medications based on current projections of critical care patient volume.

What does it mean for patients?

The findings highlight the importance of continuing to follow strict preventative measures, the CDC report said.

Pharmacists are positioned to play a key role in preventing or catching errors that can occur at the various stages of the drug-use process: prescribing, dispensing, and administration.

Expanding COVID-19 testing is "a critical component in our nation's efforts to reduce the number of cases, ease burdens on our over-utilized hospitals and clinics, and protect the safety of our communities," the Pharmacists for Healthier Lives coalition said.

Pharmacies that haven’t added digital marketing and advertising to their mix are missing the target.

The FDA has approved lumateperone tosylate (Caplyta™, Intra-Cellular Therapies) for treatment of schizophrenia in adults.

Officials with the FDA issued a warning letter to a company marketing fraudulent and dangerous chlorine dioxide products for the prevention and treatment of novel coronavirus disease 2019.